Dermatology

A groundbreaking clinical trial has provided valuable insights into the management of dermatoporosis, a condition characterized by chronic extracellular matrix (ECM) degradation leading to skin atrophy and fragility.

A recent large-scale study published in a dermatology journal provides important insights into the cardiovascular safety of biologic therapies for patients with psoriasis or psoriatic arthritis (PsA).

A new systematic review has shed light on the safety of beta blockers for treating PHACE syndrome, addressing concerns about stroke risk in patients with cerebrovascular and cardiovascular anomalies.

A recent study has highlighted metformin’s potential role in reducing the risk of non-melanoma skin cancers (NMSC), offering intriguing possibilities for dermatological and oncological care.

A new study reveals that patients with cutaneous lupus erythematosus (CLE) face significantly higher risks of atherosclerotic cardiovascular disease (ASCVD) compared to the general population.

A recent study has uncovered promising advancements in the fight against Stage II melanoma by introducing a novel biomarker technique, immune Förster resonance energy transfer (iFRET).

An epidemiological study has shed light on the primary risk factors driving Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer.

Patients with moderate-to-severe atopic dermatitis who did not initially meet response criteria for lebrikizumab at 16 weeks can still achieve improvements with continued therapy, according to a recent clinical trial analysis.